<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03084575</url>
  </required_header>
  <id_info>
    <org_study_id>IRB No.201516026.2</org_study_id>
    <nct_id>NCT03084575</nct_id>
  </id_info>
  <brief_title>Thermal Radiofrequency Versus Neurolytic Saddle Rhizotomyfor Severe Pereneal Cancer Pain</brief_title>
  <official_title>The Role of Selective Thermal Radiofrequency Saddle Rhizotomy In Managing Interactable Malignant Perineal Pain: A Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The control of perineal malignant pain is difficult and challenging for pain physicians.
      Different modalities have been tried to treat this complex pain syndrome including
      pharmacotherapy and interventional therapy.

      Neuroaxial phenol rhizolysis is simple and cheap option. However; for patients with pelvic or
      rectal neoplasms and intact bowel and bladder sphincteric functions, there are neurosurgical
      recomendations of selective sacral nerve roots rhizotomy blockade &quot;as an alternative to
      chemical saddle rhizotomy&quot;.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      40 selected patients were randomly allocated into 2 groups &quot;20 patients each&quot;

      Group 1 &quot;RF group&quot;: in which patients underwent thermal radio Frequency, selective
      (unilateral S3, bilateral S4 and S5) saddle rhizotomy.

      Group 2 &quot;phenol group&quot;: in which patients underwent hyperbaric chemical saddle rhizotomy
      using 6% phenol in glycerin.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomization was done using a computer-generated random numbers with proper concealment in opaque sealed envelopes .</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>assessment will be done by junior stuff who is blind to the technique of intervention</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in VAS</measure>
    <time_frame>baseline, one month, 3months</time_frame>
    <description>VAS: A 100mm scale, horizontal line with 2 stop ends; the left end means no pain &amp; the right end means the worst impaginable pain. It is a valid and practical scale for assessing chronic pain and for pain researches.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional improvement</measure>
    <time_frame>baseline, one month, 3 months</time_frame>
    <description>Functional improvement. It is a self-reported analysis for the primary outcome after performing pain interventions. It is divided into four categorie (0-25%) ≈ no or minimal functional improvement, (&gt; 25% to 50%) ≈ mild improvement, (&gt;50% to 75%) ≈ moderate improvement, and (&gt;75% to 100%) ≈ marked improvement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in dose of daily drug consuption</measure>
    <time_frame>base line, one month, 3 months</time_frame>
    <description>drug (opioid, pregabalin &amp; amitryptiline) consumption (mg/day) .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ODI</measure>
    <time_frame>baseline, one month, 3 months</time_frame>
    <description>(Oswestry Disability Index): Self-reported questionnaire with 10 sections each with five items designed to assess limitations of various asctivities of daily living.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGIC</measure>
    <time_frame>baseline, one month and 3 months</time_frame>
    <description>Patient satisfaction (PGIC): Patient Global Impression of Changes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Interactable Malignant Perineal Pain</condition>
  <arm_group>
    <arm_group_label>Thermal Radiofrequency group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 &quot;RF group&quot;: in which patients will receive thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>phenol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 &quot;phenol group&quot;: in which patients will recieve hyperbaric chemical saddle rhizotomy using 6% phenol in glycerin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy</intervention_name>
    <description>Thermal RF lesioning is done using Bailys RF generator. TRF parameters are 80 C, 120 seconds the TRF lesion is repeated after 180 rotation of the needle tip again after sensory and motor pre-stimulation.</description>
    <arm_group_label>Thermal Radiofrequency group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hyperbaric chemical saddle Rhizotomy (6 % pherol in glycerin)</intervention_name>
    <description>L5-S1 intrathecal injection of 0.5-1 ml of 6 % pherol in glycerin. The patient is seated in the sitting position with 30-45o leaning backwards to make the posterior sensory roots lowermost.</description>
    <arm_group_label>phenol group</arm_group_label>
    <other_name>6 % pherol in glycerin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thermal RF lesioning is done using Bailys RF generator</intervention_name>
    <arm_group_label>Thermal Radiofrequency group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cancer patients with moderate to severe perineal pain (VAS &gt; 40mm over 100 mm scale).

          -  Intractable pain not responding to adequate tolerated opioid therapy + adjuvant
             therapy after reasonable period of time for at least 4 weeks (Rad and Kallmes, 2011).

          -  Limited life expectancy &lt; 12 months (Slatakin etal 2003).

          -  Patients are continent to urine and stool (no stomas).

        Exclusion Criteria:

          -  Uncorrected coagulopathy.

          -  Local or systemic sepsis.

          -  Known allergy to the used medications.

          -  Distorted local anatomy e.g. by advanced local neoplastic growth rendering the
             procedure technically difficult or hazardous.

          -  Sign of increased intracranial tension (Mintzer and Devarajan, 2012).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dina N Abbas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute,Cairo University</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Dina Nabil Abbas</investigator_full_name>
    <investigator_title>Assistant professor of anethesia and pain management</investigator_title>
  </responsible_party>
  <keyword>neuroaxial rhizolysis -selective rhizolysis-thermal radiofrequency</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

